Primary vitreoretinal lymphoma (PVRL) is a rare type of non-Hodgkin lymphoma that affects the eyes, specifically the retina and vitreous. It typically presents as blurred vision, floaters, or loss of vision in one or both eyes. PVRL is challenging to diagnose due to its similarity to other eye conditions. Recent advances in cancer research have highlighted the importance of early detection through improved imaging techniques and molecular analysis of vitreous samples. Treatment often involves a combination of chemotherapy, radiation therapy, and intravitreal injections. However, the prognosis remains guarded, with a high risk of recurrence and potential central nervous system involvement. Ongoing research aims to elucidate the underlying mechanisms of PVRL development and identify novel targeted therapies to improve patient outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China